Multiple system atrophy

Common Name(s)

Multiple system atrophy

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by symptoms of autonomic nervous system failure such as fainting spells and bladder control problems, combined with motor control symptoms such as tremor, rigidity, and loss of muscle coordination.  MSA affects both men and women primarily in their 50s.  The disease tends to advance rapidly over the course of 9 to 10 years, with progressive loss of motor skills, eventual confinement to bed, and death. The cause of multiple system atrophy is unknown, although environmental toxins, trauma, and genetic factors have been suggested.  There is no cure for this condition, and there is no known way to prevent the disease from getting worse. The goal of treatment is to control symptoms.  
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple system atrophy" for support, advocacy or research.

Logo
National MSA Support Group

The MSA Support Group has a four pillar mission statement: 1) To support patients and caregivers 2) To educate patients, caregivers, healthcare providers, and others affected by MSA 3) To raise money for MSA research 4) to advocate and create awareness for MSA

Last Updated: 16 Nov 2012

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Multiple system atrophy" for support, advocacy or research.

Logo
National MSA Support Group

The MSA Support Group has a four pillar mission statement: 1) To support patients and caregivers 2) To educate patients, caregivers, healthcare providers, and others affected by MSA 3) To raise money for MSA research 4) to advocate and create awareness for MSA

http://www.shy-drager.org

Last Updated: 16 Nov 2012

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

General Resources

The MSA Research Fund

The MSA Research Fund is the National MSA Support Group's fund dedicated to supporting meaningful MSA research. The Support Group is a 501(c)3 so donations are tax deductible.

Updated 16 Nov 2012

Go To URL
The MSA Forum

The MSA Forum is hosted by the National MSA Support Group. The forum offers an opportunity for patients and caregivers to communicate and share with others affected by MSA.

Updated 16 Nov 2012

Go To URL
 
 
Top

Blogs

The MSA Blog

The multiple system atrophy MSA) blog is dedicated to providing relevant information about support, education, research and advocacy to those affected by MSA

Updated 16 Nov 2012

Go To URL
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Multiple system atrophy" returned 275 free, full-text research articles on human participants. First 3 results:

Familial Parkinson's point mutation abolishes multiple system atrophy prion replication.
 

Author(s): Amanda L Woerman, Sabeen A Kazmi, Smita Patel, Atsushi Aoyagi, Abby Oehler, Kartika Widjaja, Daniel A Mordes, Steven H Olson, Stanley B Prusiner

Journal: Proc. Natl. Acad. Sci. U.S.A.. 2018 01;115(2):409-414.

 

In the neurodegenerative disease multiple system atrophy (MSA), α-synuclein misfolds into a self-templating conformation to become a prion. To compare the biological activity of α-synuclein prions in MSA and Parkinson's disease (PD), we developed nine α-synuclein-YFP cell lines ...

Last Updated: 31 Dec 1969

Go To URL
Serum microRNA expression profiling in patients with multiple system atrophy.
 

Author(s): Kodai Kume, Hisakazu Iwama, Kazushi Deguchi, Kazuyo Ikeda, Tadayuki Takata, Yohei Kokudo, Masaki Kamada, Keiko Fujikawa, Kayo Hirose, Hisashi Masugata, Tetsuo Touge, Tsutomu Masaki

Journal: Mol Med Rep. 2018 Jan;17(1):852-860.

 

Multiple system atrophy (MSA) is a sporadic neurodegenerative disease that is pathologically characterized by α‑synuclein positive glial cytoplasmic inclusions in oligodendrocytes. The clinical diagnosis of MSA is often challenging as there are no established biomarkers and diagnoses ...

Last Updated: 31 Dec 1969

Go To URL
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.
 

Author(s): Ronald J Mandel, David J Marmion, Deniz Kirik, Yaping Chu, Clifford Heindel, Thomas McCown, Steven J Gray, Jeffrey H Kordower

Journal:

 

Multiple system atrophy (MSA) is a horrible and unrelenting neurodegenerative disorder with an uncertain etiology and pathophysiology. MSA is a unique proteinopathy in which alpha-synuclein (α-syn) accumulates preferentially in oligodendroglia rather than neurons. Glial cytoplasmic ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Multiple system atrophy" returned 30 free, full-text review articles on human participants. First 3 results:

Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis.
 

Author(s): Sweta Bajaj, Florian Krismer, Jose-Alberto Palma, Gregor K Wenning, Horacio Kaufmann, Werner Poewe, Klaus Seppi

Journal:

 

Putaminal diffusivity in brain magnetic resonance diffusion-weighted imaging (DWI) is increased in patients with the parkinsonian variant of multiple system atrophy (MSA-P) compared to Parkinson disease (PD) patients.

Last Updated: 31 Dec 1969

Go To URL
Multiple system atrophy: clinicopathological characteristics in Japanese patients.
 

Author(s): Tetsutaro Ozawa, Osamu Onodera

Journal: Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.. 2017 ;93(5):251-258.

 

Multiple system atrophy (MSA) is an adult-onset neurodegenerative disorder that has both clinical and pathological variants. Clinical examples include MSA with predominant cerebellar ataxia (MSA-C) and MSA with predominant parkinsonism (MSA-P), whereas olivopontocerebellar atrophy ...

Last Updated: 31 Dec 1969

Go To URL
Management of sleep disorders in Parkinson's disease and multiple system atrophy.
 

Author(s): Aleksandar Videnovic

Journal: Mov. Disord.. 2017 May;32(5):659-668.

 

Parkinson's disease (PD) and multiple system atrophy (MSA) are disorders associated with α synuclein-related neurodegeneration. Nonmotor symptoms are common hallmarks of these disorders, and disturbances of the sleep-wake cycle are among the most common nonmotor symptoms. It is only ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Futility Trial of Sirolimus in Multiple System Atrophy
 

Status: Not yet recruiting

Condition Summary: Multiple System Atrophy

 

Last Updated: 5 Jul 2018

Go to URL
Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy
 

Status: Recruiting

Condition Summary: Multiple System Atrophy

 

Last Updated: 18 Apr 2018

Go to URL